All In Biotech

Drug Trial Radar · NCT00496197

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis

Last checked: Nov 20, 2026Latest source record: Oct 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

282

Actual

Start

Jul 2007

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or tissue. Currently the drug is approved for treatment using a daily dose of IV medication until 14 days after the fungus disappears from the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it is administered for 5-28 days followed by oral antifungal medication. Study patients will be assessed for response to treatment throughout the study drug treatment period.

Conditions

  • Candidiasis

Interventions

  • Eraxis (anidulafungin)Drug

    Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.

  • Diflucan (fluconazole)Drug

    Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.

  • Vfend (voriconazole)Drug

    Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT)Time frame: End of Treatment (Day 5 up to Day 42)

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Wilmington, Delaware

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Royal Oak, Michigan

  • Pfizer Investigational Site

    Minneota, Minnesota

  • Pfizer Investigational Site

    Butte, Montana

  • Pfizer Investigational Site

    Camden, New Jersey

  • Pfizer Investigational Site

    Albany, New York

  • Pfizer Investigational Site

    Buffalo, New York

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    Greenville, North Carolina

  • Pfizer Investigational Site

    Greenville, North Carolina

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

  • Pfizer Investigational Site

    West Reading, Pennsylvania

  • Pfizer Investigational Site

    Charleston, South Carolina

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    Seoul, South Korea

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.